Abstract
This manuscript introduces and demonstrates a modification of the popular cost-effectiveness methodology. Because arbitrarily selected discount rates for future health effects can radically change the cost-effect ratio, the determinants of the ratio—differences in the present values of effects and costs—are examined for a wide range of discount rates. Treatment selection then follows directly from explicit judgments about expected patient longevity and appropriate combinations of cost and effect discount rates. The decision to select resection or enucleation of a benign prostatic hypertrophy is developed with data from a small number of clinical patients from Washington University.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Warner, K. E., and Hutton, R. C., Cost-benefit and cost-effectiveness analysis in health care.Med. Care 18:1069–1085, 1980.
Warner, K. E., and Luce, B. R.,Cost-Benefit and Cost-Effectiveness Analyses in Health Care: Principles, Practice, and Potential. Health Administration Press, Ann Arbor, Michigan, 1982.
Copeland, R., and Jacobs, P., Cost of capital, target rate of return, and investment decision making.Health Serv. Res. 16:335–341, 1981.
Pliskin, N., and Taylor, A. K., General principles: Cost-benefit and decision analysis.Costs, Risks, and Benefits of Surgery (J. P. Bunker, B. A. Barnes, and F. Mosteller, eds.), Oxford University Press, New York, 1977, pp. 5–27.
Grayhack, J. T., and Sadlowski, R.,Results of Surgical Treatment of Benign Prostatic Hyperplasia (DHEW Publication No. NIH 76-11.3), National Institutes of Health, Bethesda, Maryland, 1975.
Lytton, B., Emery, J. M., and Harvard, B. M., The incidence of benign prostatic obstruction.J. Urol. 99:639–645, 1968.
Cretin, S., Cost/benefit analysis of treatment and prevention of myocardial infarction.Health Serv. Res. 12:174–189, 1977.
Weinstein, M. C., and Stason, W. B.,Hypertension: A Policy Perspective Harvard University Press, Cambridge, Massachusetts, 1976.
Weinstein, M. C., and Stason, W. B., Foundations of cost-effectiveness analysis for health and medical practices.N. Engl. J. Med. 296:716–721, 1977.
Berwick, D. M., and Komaroff, A. L., Cost effectiveness of lead screening.N. Engl. J. Med. 306:1392–1398, 1982.
Neuhauser, D., Cost-effective clinical decision making.Pediatrics 60:756–759, 1977.
Berg, R. L. (ed.),Health Status Indexes Hospital Research and Educational Trust, Chicago, 1973.
Castro, J. E. (ed.),The Treatment of Prostatic Hypertrophy and Neoplasia University Park Press, Baltimore, 1974.
Geller, J., Medical treatment of benign prostatic hypertrophy.The Treatment of Prostatic Hypertrophy and Neoplasia (J. E. Castro, ed.), University Park Press, Baltimore, 1974, pp. 27–59.
Madsen, P., Personal letter to Dr. Saul Boyarsky in St. Louis.
Torrence, G. W., Sackett, D. L., and Thomas, W. H., Utility maximization model for program evaluation: A demonstration application.Health Status Indices (R. L. Berg, ed.), Hospital Research and Educational Trust, Chicago, 1973.
Boyarsky, S., and Boyarsky, R. E., Psychosexual counseling: Informed consent.Benign Prostatic Hypertrophy (F. Hinman, ed.), Springer-Verlag, New York, 1983.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Woodward, R., Boyarsky, S. & Barnett, H. Discounting surgical benefits. J Med Syst 7, 481–493 (1983). https://doi.org/10.1007/BF00995179
Issue Date:
DOI: https://doi.org/10.1007/BF00995179